Eledon Pharmaceuticals, Inc.
ELDN
Positions held
Your positionsELDN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $196.65M | Enterprise value | $108.36M | Trailing P/E | — | Forward P/E | -3.14 |
| PEG | — | Price / book | 2.72 | Beta | 0.85 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -110.7% | ROA | -39.0% | Debt / equity | 0.01 |
| Current ratio | 7.90 | Free cash flow | -$45.10M | Analyst recommendation | none | Mean target | $9.00 |
| 52w high | $4.60 | 52w low | $1.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$31.6M | -$39.0M | -$10.4M | -$17.5M | -$11.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.9M | -$21.2M | -$21.5M | -$19.1M | -$24.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$45.6M | -$36.2M | -$117M | -$88.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$83.3M | -$70.6M | -$43.0M | -$39.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
2026-09-11 · Top Premarket Gainers
2026-09-09 · Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
2026-09-03 · Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart
2026-08-13 · Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-21 · A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
Price (daily)
Full chart · RSI · MACD · patterns